Human cystatin F

Abstract

The invention relates to Cystatin F polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

What is claimed is:  
     
         1 . An isolated polynucleotide comprising a polynucleotide having at least a 70% identity to a member selected from the group consisting of: 
 (a) a polynucleotide encoding a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2;    (b) a polynucleotide encoding a polypeptide comprising amino acid 19 to amino acid 145 as set forth in SEQ ID NO:2;    (c) a polynucleotide which is complementary to the polynucleotide of (a) or (b); and    (d) a polynucleotide comprising at least 15 bases of SEQ ID NO:1.    
     
     
         2 . The polynucleotide of  claim 1  wherein the polynucleotide is DNA.  
     
     
         3 . The polynucleotide of  claim 1  wherein the polynucleotide is RNA.  
     
     
         4 . The polynucleotide of  claim 1  wherein the polynucleotide is genomic DNA.  
     
     
         5 . The polynucleotide of  claim 2  which encodes the polypeptide comprising amino acid 1 to 145 of SEQ ID NO:2.  
     
     
         6 . The polynucleotide of  claim 2  which encodes the polypeptide comprising amino acid 19 to 145 of SEQ ID NO:2.  
     
     
         7 . An isolated polynucleotide comprising a polynucleotide having at least a 70% identity to a member selected from the group consisting of: 
 (a) a polynucleotide which encodes a mature polypeptide having the amino acid sequence expressed by the human cDNA contained in ATCC Deposit No. 97463;    (b) a polynucleotide which is complementary to the polynucleotide of (a); and    (c) a polynucleotide comprising at least 15 bases of the polynucleotide of either (a) or (b).    
     
     
         8 . The polynucleotide of  claim 1  comprising the sequence as set forth in SEQ ID NO:1 from nucleotide 1 to nucleotide 633.  
     
     
         9 . The polynucleotide of  claim 1  comprising the sequence as set forth in SEQ ID NO:1 from nucleotide 112 to nucleotide 633.  
     
     
         10 . A vector comprising the DNA of  claim 2 .  
     
     
         11 . A host cell comprising the vector of  claim 10 .  
     
     
         12 . A process for producing a polypeptide comprising: expressing from the host cell of  claim 11  the polypeptide encoded by said DNA.  
     
     
         13 . A process for producing a cell which expresses a polypeptide comprising genetically engineering a cell with the vector of  claim 10 .  
     
     
         14 . A polypeptide comprising a member selected from the group consisting of: 
 (a) a polypeptide having an amino acid sequence set forth in SEQ ID NO:2;    (b) a polypeptide comprising amino acid 19 to 145 of SEQ ID NO:2; and    (c) a polypeptide which is at least 70% identical to the polypeptide of either (a) or (b).    
     
     
         15 . The polypeptide of  claim 14  wherein the polypeptide comprises amino acid 1 to amino acid 145 of SEQ ID NO:2.  
     
     
         16 . The polypeptide of  claim 14  wherein the polypeptide comprises amino acid 19 to amino acid 145 of SEQ ID NO:2.  
     
     
         17 . A compound which inhibits activation of the polypeptide of  claim 14 .  
     
     
         18 . A compound which activates the polypeptide of  claim 14 .  
     
     
         19 . A method for the treatment of a patient having need of Cystatin F comprising administering to the patient a therapeutically effective amount of the polypeptide of  claim 14 .  
     
     
         20 . The method of  claim 19  wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.  
     
     
         21 . A method for the treatment of a patient having need to inhibit a Cystatin F polypeptide comprising administering to the patient a therapeutically effective amount of the compound of  claim 17 .  
     
     
         22 . A process for diagnosing a disease or a susceptibility to a disease related to an under-expression of the polypeptide of  claim 14  comprising determining a mutation in a nucleic acid sequence encoding said polypeptide.  
     
     
         23 . A diagnostic process comprising analyzing for the presence of the polypeptide of  claim 14  in a sample derived from a host.  
     
     
         24 . A method for identifying compounds which bind to and inhibit activation of the polypeptide of  claim 14  comprising: 
 (a) contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with an analytically detectable Cystatin F polypeptide and a compound under conditions to permit binding to the receptor; and  
 (b) determining whether the compound binds to and inhibits the receptor by detecting the absence of a signal generated from the interaction of the Cystatin F with the receptor.